|Articles|October 1, 2016
Best Practices in Study Feasibility
Author(s)ISR
Survey drills down on the preferred methods of sponsors, CROs, and sites in conducting feasibility analysis.
Advertisement
Successfully navigating the medical, clinical, logistical and regulatory challenges associated with establishing the feasibility of a clinical trial is not easy. Insights from sponsos, contract research organizations (CROs) and sites have been compiled in ISR’s Best Practices in Study Feasibility report. A particular area of interest for readers of the report are the techniques and innovations proffered by sponsors and CROs for conducting feasibility analyses. Both groups identified that the integration of statistical modeling and knowledge of past performance into feasibility analyses is positively impacting the process.
Sponsors also see value in making direct, personal contact with investigators to build better relationships and a greater use of electronic medical record (EMR) data as positive innovations. CROs point to improved feasibility surveys and better targeting questions as ways to improve study feasibility estimations. ISR also collected insights to improve the accuracy of study feasibility estimates including: the percentage of trials that require a feasibility analysis, and whether the analysis is conducted in-house or outsourced; awareness of feasibility analysis service providers and frequency of use; and the data sources utilized for feasibility analyses and a ranking of which data sources contribute to the accuracy of the estimate.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
3
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5